Tags » Hemophilia A

Orphan Drugs: FDA Approval of Baxter’s Treatment For Rare Form of Hemophilia

On October 24th, the FDA announces the approval of Baxter International’s orphan drug Obizur for the treatment of bleeding episodes in adults with Acquired Hemophilia A (AHA) (acquired Factor VIII deficiency). 266 more words

Orphan Drug Development

Baxter Announces Results from Its Study of BAX 855

Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients

Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand… 1,138 more words


European Commission publishes approval of Octapharma’s human cell line recombinant FVIII (Nuwiq®) across all age groups in haemophilia A


Lachen, Switzerland, August 5th, 2014: The European Commission has published approval of Octapharma’s Nuwiq® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital factor VIII deficiency). 575 more words